📊 SHPH Key Takeaways
Is Shuttle Pharmaceuticals Holdings, Inc. (SHPH) a Good Investment?
Shuttle Pharmaceuticals faces critical financial distress with only $334K cash while burning $9.5M annually, creating severe going concern risk within weeks. Minimal revenue of $100K with zero growth and $11.9M operating losses indicate failed drug commercialization. The current ratio of 0.06x signals inability to meet short-term obligations, positioning the company for restructuring or insolvency.
Why Buy Shuttle Pharmaceuticals Holdings, Inc. Stock? SHPH Key Strengths
- Debt-to-equity ratio of 0.19x limits leverage exposure relative to equity base
- Total liabilities of $8.2M provide some liquidation value potential
- Pharmaceutical IP portfolio may retain acquisition value in restructuring
SHPH Stock Risks: Shuttle Pharmaceuticals Holdings, Inc. Investment Risks
- Cash runway of approximately 2 weeks at current $9.5M annual burn rate
- Current ratio of 0.06x indicates acute liquidity crisis and inability to service current liabilities
- Zero revenue growth and minimal $100K annual revenue suggests complete commercialization failure
- Operating cash burn unsustainable without immediate capital infusion or strategic transaction
- Negative interest coverage of -14.3x indicates operational inability to service debt
- No insider Form 4 activity in 90 days reflects lack of management confidence
Key Metrics to Watch
- Cash balance and weeks of runway remaining
- Quarterly revenue and operating cash burn trajectory
- Current ratio and working capital adequacy for debt covenant compliance
- Clinical trial progression and regulatory pathway for pipeline assets
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
SHPH Profit Margin, ROE & Profitability Analysis
SHPH vs Healthcare Sector: How Shuttle Pharmaceuticals Holdings, Inc. Compares
How Shuttle Pharmaceuticals Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Shuttle Pharmaceuticals Holdings, Inc. Stock Overvalued? SHPH Valuation Analysis 2026
Based on fundamental analysis, Shuttle Pharmaceuticals Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Shuttle Pharmaceuticals Holdings, Inc. Balance Sheet: SHPH Debt, Cash & Liquidity
SHPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Shuttle Pharmaceuticals Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-82.60 indicates the company is currently unprofitable.
SHPH Revenue Growth, EPS Growth & YoY Performance
Shuttle Pharmaceuticals Holdings, Inc. Dividends, Buybacks & Capital Allocation
SHPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SHPH
What is the AI rating for SHPH?
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has an AI rating of STRONG SELL with 93% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SHPH's key strengths?
Claude: Debt-to-equity ratio of 0.19x limits leverage exposure relative to equity base. Total liabilities of $8.2M provide some liquidation value potential.
What are the risks of investing in SHPH?
Claude: Cash runway of approximately 2 weeks at current $9.5M annual burn rate. Current ratio of 0.06x indicates acute liquidity crisis and inability to service current liabilities.
What is SHPH's revenue and growth?
Shuttle Pharmaceuticals Holdings, Inc. reported revenue of $100.0K.
Does SHPH pay dividends?
Shuttle Pharmaceuticals Holdings, Inc. does not currently pay dividends.
Where can I find SHPH SEC filings?
Official SEC filings for Shuttle Pharmaceuticals Holdings, Inc. (CIK: 0001757499) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SHPH's EPS?
Shuttle Pharmaceuticals Holdings, Inc. has a diluted EPS of $-7.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SHPH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Shuttle Pharmaceuticals Holdings, Inc. has a STRONG SELL rating with 93% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SHPH stock overvalued or undervalued?
Valuation metrics for SHPH: ROE of -519.9% (sector avg: 15%), net margin of -11,721.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SHPH stock in 2026?
Our dual AI analysis gives Shuttle Pharmaceuticals Holdings, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SHPH's free cash flow?
Shuttle Pharmaceuticals Holdings, Inc.'s operating cash flow is $-9.5M, with capital expenditures of $19.0K. FCF margin is -9,500.7%.
How does SHPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -11,721.7% (avg: 12%), ROE -519.9% (avg: 15%), current ratio 0.06 (avg: 2).